Institute of Environmental Medicine, Division of Toxicology, Karolinska Institutet, Box 210, Stockholm SE-17177, Sweden.
Mol Aspects Med. 2010 Feb;31(1):60-74. doi: 10.1016/j.mam.2009.12.004. Epub 2009 Dec 6.
The last decade has witnessed a renaissance of Otto Warburg's fundamental hypothesis, which he put forward more than 80 years ago, that mitochondrial malfunction and subsequent stimulation of cellular glucose utilization lead to the development of cancer. Since most tumor cells demonstrate a remarkable resistance to drugs that kill non-malignant cells, the question has arisen whether such resistance might be a consequence of the abnormalities in tumor mitochondria predicted by Warburg. The present review discusses potential mechanisms underlying the upregulation of glycolysis and silencing of mitochondrial activity in cancer cells, and how pharmaceutical intervention in cellular energy metabolism might make tumor cells more susceptible to anti-cancer treatment.
过去十年见证了奥托·瓦尔堡(Otto Warburg)80 多年前提出的基本假设的复兴,即线粒体功能障碍和随后的细胞葡萄糖利用刺激导致癌症的发展。由于大多数肿瘤细胞对杀死非恶性细胞的药物具有显著的耐药性,因此出现了这样一个问题,即这种耐药性是否可能是瓦尔堡(Warburg)所预测的肿瘤线粒体异常的结果。本综述讨论了癌细胞中糖酵解上调和线粒体活性沉默的潜在机制,以及药物干预细胞能量代谢如何使肿瘤细胞更容易接受抗癌治疗。